arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Universe Pharmaceuticals INC

UPC

$5.76 ▼ -0.29 (-4.87%) at close

8 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

Universe Pharmaceuticals INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.6M

Dividend Yield —

Revenue Growth -22.4% ↘

Op. Margin -16.3% ↗

ROIC -4.1% ↗

FCF / Share None

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity 0.13

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$17.86B

↓ -22.4% —

Net Income Profit after all expenses

$-3.67B

↑ +57.9% —

Operating Margin Operating profit as % of sales

-16.3%

↑ +53.1% 11th

FCF / Share Free cash flow per share

$0.30

↑ +559.1% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns

Financial Health ↑

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗	FY 2020 Sep 30, 2020 20-F ↗	FY 2019 Sep 30, 2019 20-F ↗	FY 2018 Sep 30, 2018 20-F ↗
Revenue Growth YoY (%)	-22.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-380%)	71163.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+889448%)	-19.5% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-344%)	-16.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-304%)	56.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+603%)	-7.6% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-195%)	—	—
EPS Growth YoY (%)	98.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-36780.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-325.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	—	—
Net Income Growth YoY (%)	57.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-141506.5% Weak ↓ Weak Declining Year-over-year change in net income	29.5% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	49.8% Excellent Excellent Year-over-year change in net income	0.1% Caution Caution Year-over-year change in net income	—	—
FCF Growth YoY (%)	—	—	N/M	50.9% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	663.4% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	682.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	1.7% Weak Weak Compound annual revenue growth over 3 years	6.5% Fair Fair Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	257.2% Excellent Excellent Compound annual revenue growth over 5 years	269.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗	FY 2020 Sep 30, 2020 20-F ↗	FY 2019 Sep 30, 2019 20-F ↗	FY 2018 Sep 30, 2018 20-F ↗
Operating Margin (%) (%)	-16.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-209%)	-34.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-332%)	-10.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-173%)	—	—	33.4% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+123%)	29.4% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+96%)	—
Effective Tax Rate (%) (%)	—	-7.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-60.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-9.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	17.2% Good ↓ Good Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	25.2% Caution Caution Actual taxes paid relative to pre-tax income Optimal: 15-25%	21.8% Fair Fair Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-20.6% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-271%)	-37.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-416%)	-19.1% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-259%)	-21.8% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-281%)	23.6% Excellent → Excellent Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+97%)	24.6% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+105%)	22.7% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+89%)	—
FCF Margin (%) (%)	-29.8% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-42.2% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	3.3% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-3.5% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-5.2% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	19.7% Good Good Free cash flow as a percentage of revenue Optimal: > 10%	39.5% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	1.45x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.11x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	-0.17x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.16x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.22x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.74x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗	FY 2020 Sep 30, 2020 20-F ↗	FY 2019 Sep 30, 2019 20-F ↗	FY 2018 Sep 30, 2018 20-F ↗
Return on Invested Capital (%)	-4.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-18.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-14.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	36.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	61.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-4.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-6.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	35.6% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-6.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	-19.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-228%)	-15.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-204%)	-18.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-225%)	19.2% Good ↓ Good Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+28%)	36.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+142%)	61.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+307%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗	FY 2020 Sep 30, 2020 20-F ↗	FY 2019 Sep 30, 2019 20-F ↗	FY 2018 Sep 30, 2018 20-F ↗
Debt to Equity (x)	0.13x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-79%)	0.13x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-79%)	0.01x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-98%)	0.08x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-86%)	0.07x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-88%)	0.13x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-79%)	—	—
Interest Coverage (x)	-10.08x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-26.34x Weak Weak Operating income divided by interest expense Optimal: > 5x	-22.49x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	82.84x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	75.45x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$7.15B	$5.86B	$411.18K	$3.94M	$4.33M	$-7.41M	$-3.18M	$-6.19M
Debt / EBITDA (x)	-2.98x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.78x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.14x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	0.25x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗	FY 2020 Sep 30, 2020 20-F ↗	FY 2019 Sep 30, 2019 20-F ↗	FY 2018 Sep 30, 2018 20-F ↗
Revenue per Share (USD)	—	—	$8.91	$1.85	$2.53	—	—	—
Basic EPS, GAAP (USD)	$-8.06	$-626.96	$-1.70	$-0.40	$0.60	—	—	—
Free Cash Flow per Share (USD)	—	—	$0.30	$-0.06	$-0.13	—	—	—
Book Value per Share (USD)	—	—	$10.91	$2.14	$2.71	$1.30	—	—
Tangible Book Value per Share (USD)	—	—	$10.86	$2.13	$2.70	$1.29	—	—
Basic Weighted Avg Shares (shares)	455,871	13,920	3.62M	21.75M	18.98M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗	FY 2020 Sep 30, 2020 20-F ↗	FY 2019 Sep 30, 2019 20-F ↗	FY 2018 Sep 30, 2018 20-F ↗
Working Capital (USD)	$40.43B	$31.32B	$23.06M	$28.41M	$39.27M	$15.28M	—	—
Total Equity (USD)	$56.13B	$45.50B	$39.53M	$46.44M	$58.93M	$20.80M	$12.38M	$9.68M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗	FY 2020 Sep 30, 2020 20-F ↗	FY 2019 Sep 30, 2019 20-F ↗	FY 2018 Sep 30, 2018 20-F ↗
Sales/Revenue/Turnover (USD)	$17.86B	$23.02B	$32.31M	$40.14M	$47.98M	$30.70M	$33.23M	—
Depreciation Expense (USD)	$517.43M	$485.73M	$508.79K	$533.95K	$446.88K	$404.95K	$413.20K	—
Net Income, GAAP (USD)	$-3.67B	$-8.73B	$-6.16M	$-8.74M	$11.32M	$7.56M	$7.55M	—
Operating Cash Flow (USD)	$-5.05B	$-9.51B	$1.12M	$-1.31M	$-2.06M	$6.12M	$13.20M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 8 quarters

Universe Pharmaceuticals INC

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare UPC with peers